研究等業績 - その他 - 三浦　昌朋

Predictive factors for first dose reduction and interruption of lenvatinib after beginning of the standard dose in Japanese patients with thyroid cancer

Fujita K.

Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology )  95 ( 1 )   2025年12月

DOI

高速液体クロマトグラフィ分析装置LM1010を用いたフェニトインとカルバマゼピンの同時血中濃度定量と化学発光免疫測定法との比較

赤嶺 由美子, 松下 美由紀, 森川 悟, 三浦 昌朋

医療薬学 ( 一般社団法人日本医療薬学会 )  50 ( 9 ) 465 - 472   2024年09月

<p>LM1010 high-performance liquid chromatography system was recently approved as a medical diagnostic device. Phenytoin and carbamazepine—the antiepileptic drugs—can be detected simultaneously using LM1010; however, the accuracy of quantification of these two drugs in serum using this system has not been established. Herein, we compared the performance of LM1010 in measuring phenytoin and carbamazepine with that of an established chemiluminescent immunoassay (CLIA）using the ARCHITECT system. When CLIA calibrator samples were examined using both methods, the accuracy of LM1010 was within 3.20％ for phenytoin and 6.50％ for carbamazepine. Moreover, the two methods were applied to serum samples from subjects taking phenytoin (n = 95）or carbamazepine (n = 69). The slopes of Deming regression curves comparing LM1010 to CLIA for phenytoin and carbamazepine were 0.984 and 0.943, respectively. Further, Bland–Altman analyses showed an average positive bias (±1.96 × SD）of 0.180 (−1.998 – 2.359）μg/mL for phenytoin and 0.001 (−1.171 – 1.174）μg/mL for carbamazepine using LM1010 relative to CLIA. There were strong correlations between results from LM1010 and CLIA for serum phenytoin and carbamazepine (Spearman’s <i>r</i> = 0.9836 and 0.9754, respectively). The difference in the measurements of serum concentrations of carbamazepine was partially yet significantly negatively correlated with serum hemoglobin (slope = −0.1094). Thus, we successfully applied LM1010 to the simultaneous determination of serum concentrations of phenytoin and carbamazepine and concluded that this system can be used for routine therapeutic drug monitoring.</p>

DOI CiNii Research

Safety and efficacy of asciminib in a patient with chronic myeloid leukemia on hemodialysis

Naka R.

International Journal of Hematology ( International Journal of Hematology )  121 ( 2 ) 272 - 275   2024年

DOI

Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma

Numakura K.

Cancer Biology and Therapy ( Cancer Biology and Therapy )  25 ( 1 )   2024年

DOI

Association between albumin–bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients

Fujita K.

Investigational New Drugs ( Investigational New Drugs )  42 ( 3 ) 252 - 260   2024年

DOI

Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia

Kobayashi T.

Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology )  94 ( 2 ) 285 - 296   2024年

DOI

A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial)

Ureshino H.

International Journal of Hematology ( International Journal of Hematology )  120 ( 4 ) 492 - 500   2024年

DOI

Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia

Kobayashi Takahiro, Honami Sato, Miura Masatomo, Fukushi Yayoi, Kuroki Wataru, Ito Fumiko, Teshima Kazuaki, Watanabe Atsushi, Fujishima Naohito, Kobayashi Isuzu, Kameoka Yoshihiro, Takahashi Naoto

Cancer Chemotherapy and Pharmacology ( Springer Nature )    2024年

CiNii Research

Effects of CYP3A5 polymorphism and renal impairment on the drug interaction between venetoclax and fluconazole in acute myeloid leukaemia patients

Kobayashi T.

Xenobiotica ( Xenobiotica )    2024年

DOI

Effects of the Japanese Kampo Medicines Rikkunshito, Shakuyakukanzoto and Goreisan on Lenvatinib Plasma Concentrations in Japanese Patients with Thyroid Cancer

Fujita K.

Drugs - Real World Outcomes ( Drugs - Real World Outcomes )    2024年

DOI

Machine learning prediction of drug dynamics in dasatinib

Mutsu R.

Proceedings - 2024 12th International Symposium on Computing and Networking Workshops, CANDARW 2024 ( Proceedings - 2024 12th International Symposium on Computing and Networking Workshops, CANDARW 2024 )    400 - 402   2024年

DOI

Quantitation of Venetoclax in Human Plasma by High-Performance Liquid Chromatography with Ultraviolet Detection

Fukuda N.

Journal of chromatographic science ( Journal of chromatographic science )  62 ( 1 ) 58 - 64   2023年12月

DOI

Effects of polymorphisms in pregnane X receptor and ABC transporters on afatinib in Japanese patients with non-small cell lung cancer: pharmacogenomic–pharmacokinetic and exposure–response analysis

Yokota H.

Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology )  92 ( 4 ) 315 - 324   2023年10月

DOI

A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety

Fukuhara T.

Biomedicines ( Biomedicines )  11 ( 9 )   2023年09月

DOI

Evaluation of Plasma Concentrations of Mycophenolic Acid in Renal Transplant Patients Using LM1010 High-performance Liquid Chromatography

Akamine Y.

Yakugaku Zasshi ( Yakugaku Zasshi )  143 ( 4 ) 377 - 383   2023年

<p>Plasma concentrations of mycophenolic acid (MPA), an immunosuppressive agent, have been measured in clinical settings using immunoassay methods or HPLC. However, immunoassay methods show cross-reactivity with metabolites of MPA glucuronide. Recently, the LM1010 high-performance liquid chromatography instrument was approved as a new general medical device. In this study, we compared the results of MPA plasma concentrations analyzed using the LM1010 method and the previously described HPLC method. Plasma samples obtained from 100 renal transplant patients (32 women and 68 men) were evaluated using both HPLC instruments. Deming regression analyses showed a very high correlation between the two instruments, with a slope of 0.9892 and an intercept of 0.0235 µg/mL (<i>r</i>²=0.982). Bland–Altman analysis showed an average of −0.0012 µg/mL between the LM1010 method and the previously described HPLC method. For the LM1010 method, the total run time for MPA analysis was 7 min, and the analytical time was short; however, the extraction recovery when using a spin column was extremely low for frozen plasma samples stored at −20°C for 1 month, and the volume required for the assay (150 µL) could not be collected. Thus, for the LM1010 method, analysis using fresh plasma samples was optimal. Overall, our findings showed that the LM1010 method was a rapid, accurate HPLC assay for MPA analysis and could be used in clinical practice for routine monitoring of MPA in fresh plasma samples.</p>

DOI PubMed CiNii Research

Determination of Plasma Concentrations of Imatinib by a Novel Automated Analyzer Based on High-Performance Liquid Chromatography

Fukushi Y.

Yakugaku Zasshi ( Yakugaku Zasshi )  143 ( 11 ) 963 - 969   2023年

<p>LM1010 HPLC is an emerging automated method designed for use in clinical settings. The aim of this study was to compare the analytical performance of LM1010 with the performance of traditional HPLC and LC-MS/MS in the measurement of plasma concentrations of imatinib. Seventy-eight plasma samples from 20 patients (14 men and 6 women) were collected. Plasma concentrations of imatinib in samples from the same patient were analyzed simultaneously using LM1010, HPLC and LC-MS/MS (LSI Medience Corporation). Strong correlations were seen in pairwise comparisons of results from the LM1010 and HPLC methods, the LM1010 and LC-MS/MS methods, and the LC-MS/MS and HPLC methods (Spearman’s <i>r</i>=0.936, 0.906, and 0.953, respectively); however, the results from the LC-MS/MS method showed a positive proportional bias in comparison with the results from the LM1010 and HPLC methods, according to Deming analyses (slope=1.064 and 1.105, respectively). In Bland–Altman analyses, the LC-MS/MS method showed a positive mean bias of 98.6 and 112 ng/mL in comparison with the LM1010 and HPLC methods, respectively. Notably, results obtained using the LM1010 method were comparable to those using the HPLC method (positive mean bias=13.6 ng/mL; 95% confidence interval, −7.9–35.1 ng/mL). Biochemical parameters or drugs taken concomitantly with imatinib were not found to affect the bias of the LM1010 method. The LM1010 method can be applied to routine therapeutic drug monitoring of imatinib.</p>

DOI CiNii Research

Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors

Nakahara Y.

Frontiers in Cell and Developmental Biology ( Frontiers in Cell and Developmental Biology )  11   2023年

DOI

A Multi-institutional Study to Diagnose the Risk of Lymph Node Metastasis Using a CRP Genetic Polymorphism Test Kit in pT1, cN0 Thoracic Esophageal Squamous Cell Carcinoma

Motoyama S.

Anticancer Research ( Anticancer Research )  42 ( 12 ) 6105 - 6112   2022年12月

DOI

Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients

Yagishita H.

International Journal of Molecular Sciences ( International Journal of Molecular Sciences )  23 ( 19 )   2022年10月

DOI

Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia

Sato H.

Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology )  90 ( 3 ) 279 - 284   2022年09月

DOI

次世代の薬剤師を支えるTDMエビデンスの創出

尾田 一貴, 三浦 昌朋, 榎屋 友幸

日本医療薬学会年会講演要旨集 ( 一般社団法人 日本医療薬学会 )  32 ( 0 ) 288 - 293   2022年09月

DOI CiNii Research

Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy

Fukuda N.

Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology )  89 ( 5 ) 609 - 616   2022年05月

DOI

Associations Between Plasma Concentrations of Lenvatinib and Angiopoietin and Clinical Responses to Lenvatinib Therapy in Japanese Patients With Thyroid Cancer

Kumagai M.

Cancer Diagnosis and Prognosis ( Cancer Diagnosis and Prognosis )  2 ( 3 ) 336 - 344   2022年

DOI

Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer

Yokota H.

Investigational New Drugs ( Investigational New Drugs )  40 ( 6 ) 1254 - 1262   2022年

DOI CiNii Research

Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate

Takahashi Y.

European Journal of Clinical Pharmacology ( European Journal of Clinical Pharmacology )  79 ( 1 ) 89 - 98   2022年

DOI

Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome-positive acute lymphoblastic leukaemia patients

Fukushi Y.

British Journal of Clinical Pharmacology ( British Journal of Clinical Pharmacology )  89 ( 5 ) 1695 - 1700   2022年

DOI

Effects of SLC22A2 808G&gt;T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy

Abumiya M.

Scientific Reports ( Scientific Reports )  11 ( 1 )   2021年12月

DOI

Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial

Murai K.

The Lancet Haematology ( The Lancet Haematology )  8 ( 12 ) e902 - e911   2021年12月

DOI

Regulatory t cell as a biomarker of treatment-free remission in patients with chronic myeloid leukemia

Fujioka Y.

Cancers ( Cancers )  13 ( 23 )   2021年12月

DOI

Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL

Kawano N.

International Journal of Hematology ( International Journal of Hematology )  114 ( 4 ) 509 - 516   2021年10月

DOI

Relationship between plasma concentrations of afatinib and the onset of diarrhea in patients with non-small cell lung cancer

Yokota H.

Biology ( Biology )  10 ( 10 )   2021年10月

DOI

TDMエビデンスの創出・進化に向けたあくなき挑戦

尾田 一貴, 三浦 昌朋, 榎屋 友幸

日本医療薬学会年会講演要旨集 ( 一般社団法人 日本医療薬学会 )  31 ( 0 ) S27 - S27   2021年10月

DOI CiNii Research

Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance

Abumiya M.

Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics )  46 ( 1 ) 219 - 222   2021年02月

DOI

Effects of SLC31A1 and ATP7B polymorphisms on platinum resistance in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy

Fujita K.

Medical Oncology ( Medical Oncology )  38 ( 1 )   2021年01月

DOI

The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration

Ito F.

International Journal of Hematology ( International Journal of Hematology )  113 ( 1 ) 100 - 105   2021年01月

DOI

Results of a nationwide survey of Japanese pharmacists regarding the application of pharmacogenomic testing in precision medicine

Tsuji D.

Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics )  46 ( 3 ) 649 - 657   2021年

DOI

Effects on monotherapy and reduction of antipsychotic drugs by clozapine therapy in Japanese patients with treatment-resistant schizophrenia

Akamine Y.

Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics )  46 ( 5 ) 1312 - 1318   2021年

DOI

Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute

Kidoguchi K.

International Journal of Hematology ( International Journal of Hematology )  114 ( 2 ) 199 - 204   2021年

DOI

Tacrolimus concentrations after renal transplantation in a mother-neonate dyad: Maternal, neonatal and breast milk measurements

Akamine Y.

Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics )  46 ( 6 ) 1800 - 1803   2021年

DOI

Association between ABCC2 polymorphism and hematological toxicity in patients with esophageal cancer receiving platinum plus 5-fluorouracil therapy

Fujita K.

Esophagus ( Esophagus )  19 ( 1 ) 146 - 152   2021年

DOI

ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib

Sakamoto S.

Investigational New Drugs ( Investigational New Drugs )  38 ( 6 ) 1687 - 1695   2020年12月

DOI

Does the Addition of Abiraterone to Castration Affect the Reduction in Bone Mineral Density?

Nakajima S.

In Vivo ( In Vivo )  34 ( 6 ) 3291 - 3299   2020年11月

DOI

The impact of hemodialysis and liver cirrhosis on the plasma concentrations of tyrosine kinase inhibitors in a patient with chronic myeloid leukemia

Taniguchi Y.

Internal Medicine ( Internal Medicine )  59 ( 21 ) 2745 - 2749   2020年11月

<p>We recently treated a chronic myeloid leukemia (CML) patient with liver and renal dysfunction, who was undergoing hemodialysis (HD). He was treated with 50 mg dasatinib (DAS) once daily just before HD. The maximum plasma concentration of DAS was 227 ng/mL on a non-HD day and 46.9 ng/mL on a HD day. He was subsequently treated with 200 mg bosutinib (BOS) once daily. The plasma concentration of BOS changed from 74.5 ng/mL before HD to 58.8 ng/mL after HD. Our results indicate that close monitoring of the plasma tyrosine kinase inhibitor concentrations should be considered in CML patients with organ impairment. </p>

DOI PubMed CiNii Research

TDM研究が見出すクリニカル・クエスチョンとエビデンスの創出

三浦 昌朋, 尾田 一貴, 榎屋 友幸

日本医療薬学会年会講演要旨集 ( 一般社団法人 日本医療薬学会 )  30 ( 0 ) 390 - 395   2020年10月

DOI CiNii Research

令和の時代に求められる医療薬学研究とは

内藤 隆文, 三浦 昌朋, 川上 純一

日本医療薬学会年会講演要旨集 ( 一般社団法人 日本医療薬学会 )  30 ( 0 ) 420 - 425   2020年10月

DOI CiNii Research

A comparison of laparoendoscopic single-site surgery versus conventional procedures for laparoscopic donor nephrectomy: a Japanese multi-institutional retrospective study

Inoue T.

Surgical Endoscopy ( Surgical Endoscopy )  34 ( 8 ) 3424 - 3434   2020年08月

DOI

Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR-mutation positive non-small cell lung cancer

Yokota H.

Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics )  45 ( 4 ) 652 - 659   2020年08月

DOI

Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease

Mori J.

International Journal of Hematology ( International Journal of Hematology )  112 ( 1 ) 115 - 117   2020年07月

DOI

特集 がん薬物療法と腎機能低下　腎機能を考慮したマネジメントの基礎と実践 慢性腎臓病/腎不全を合併するがん患者で注意すべきがん薬物療法　慢性骨髄性白血病の分子標的抗がん薬

三浦 昌朋

薬局 ( (株)南山堂 )  71 ( 7 ) 2674 - 2679   2020年06月

DOI CiNii Research

Changes in PCSK9 and LDL cholesterol concentrations by everolimus treatment and their effects on polymorphisms in PCSK9 and mTORC1

Sato S.

Pharmacological Reports ( Pharmacological Reports )  72 ( 3 ) 622 - 630   2020年06月

DOI

Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities

Taguchi D.

International Journal of Clinical Oncology ( International Journal of Clinical Oncology )  25 ( 4 ) 531 - 540   2020年04月

DOI

特集 調剤業務Update　薬剤師の貢献と発信されたエビデンス総まとめ 医薬品の廃棄に対する取り組みとその効果　医療用麻薬の廃棄とその削減対策

加藤 正太郎, 三浦 昌朋

薬局 ( (株)南山堂 )  71 ( 2 ) 307 - 312   2020年02月

DOI CiNii Research

Effects of proprotein convertase subtilisin/kexin type 9 and nilotinib plasma concentrations on nilotinib-induced hypercholesterolaemia in patients with chronic myeloid leukaemia

Abumiya M.

Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics )  46 ( 2 ) 382 - 387   2020年

DOI

Quantification of the Plasma Concentrations of Perampanel Using High-Performance Liquid Chromatography and Effects of the CYP3A4* 1G Polymorphism in Japanese Patients

Ohkubo S.

Journal of Chromatographic Science ( Journal of Chromatographic Science )  58 ( 10 ) 915 - 921   2020年

DOI

薬学的視点に基づいたプレシジョン・メディシンの国内基盤構築のための調査研究

辻 大樹, 斎藤 嘉朗, 莚田 泰誠, 三浦 昌朋, 平 大樹, 寺田 智祐

医療薬学 ( 一般社団法人日本医療薬学会 )  46 ( 2 ) 66 - 76   2020年

<p>Given that the cancer gene panel test was approved in June 2019, precision medicine based on the information about somatic mutation is expected to be widely available. Similarly, pharmacogenomics (PGx) associated with germline genes, such as drug-metabolizing enzymes, could also be effective tools. However, its clinical implementation has been delayed.</p><p>To address this issue, we conducted a survey regarding pharmacists' involvement in "cancer genomic medicine (CGM)" and actual use of PGx and therapeutic drug monitoring (TDM). The response rate of the survey was 96.8％ (121/125).</p><p>According to this survey, genetic polymorphism analysis for irinotecan (UGT1A1), which is approved for genetic testing, was most commonly used. Among the tests not covered by insurance, tacrolimus (CYP3A5) and voriconazole (CYP2C19) were commonly used. Only a few facilities conducted PGx tests. Unlike PGx, many drugs are covered by insurance for TDM, which was commonly used. Vancomycin was most commonly used, followed by teicoplanin and cyclosporine. Regarding CGM, it was found that the pharmacists were most commonly involved in dose adjustment support, followed by support for selection of anti-cancer agents. Pharmacists' participation in the expert panel was 21.3％.</p><p>This survey revealed that PGx testing is less common compared with TDM. PGx of drug-metabolizing enzymes could potentially influence adverse reactions and efficacy. It might be possible to provide individualized pharmacotherapy if PGx testing could be performed at the same time as gene panel tests. Insurance-covered PGx testing may increase in the future if more high-quality clinical trials are conducted and its usefulness is validated.</p>

DOI CiNii Research

腎移植患者におけるエベロリムス投与後の脂質異常症発現の機序解明

加賀谷 英彰, 赤嶺 由美子, 佐藤 汐莉, 齊藤 満, 沼倉 一幸, 羽渕 友則, 佐藤 滋, 三浦 昌朋

移植 ( 一般社団法人 日本移植学会 )  55 ( 0 ) 369_2 - 369_2   2020年

<p>【目的】mTOR阻害薬エベロリムス (EVR) の副作用に脂質異常症があるが、機序解明に繋がる臨床データは少ない。今回LDLコレステロールとその上昇に関与するPCSK9濃度に及ぼすEVRの影響と、mTORC1及びPCSK9遺伝子多型の影響について検討した。【方法】腎移植患者53名を対象に、患者背景、EVR血中濃度、PCSK9濃度を調査した。さらにmTORC1及びPCSK9遺伝子多型との関連を解析した。【結果】EVR投与後のPCSK9濃度は投与前に比べ有意に高く(214 vs 295ng/mL、P=0.004)、EVR AUC0-12とPCSK9濃度変化率との間に有意な相関が認められた (r=0.316、P=0.021)。加えてEVR投与後のPCSK9濃度変化率がmTORC1 rs2295080Gアレル保有患者で有意に高かった(P=0.006)。一方、PCSK9遺伝子多型およびLDLコレステロール濃度変化率は、PCSK9濃度変化率と相関しなかった。多変量解析よりmTORC1 rs2295080Gアレル保有患者、EVR AUC0-12、及び女性においてEVR投与後のPCSK9変化率の上昇に独立性が認められた。【考察】EVR誘発脂質異常症はPCSK9を介した機序が示唆された。さらにLDLコレステロール上昇は、PCSK9上昇と同時に起こるのではなく、その後徐々に上昇すると考える。</p>

DOI

新規TDM対象薬への対応と展望

三浦 昌朋

日本病院薬剤師会雑誌   56   977 - 981   2020年

CiNii Research

腎移植患者におけるエベロリムス投与後の脂質異常症発現の機序解明

加賀谷 英彰, 赤嶺 由美子, 佐藤 汐莉, 齊藤 満, 沼倉 一幸, 羽渕 友則, 佐藤 滋, 三浦 昌朋

移植 ( 一般社団法人 日本移植学会 )  55 ( Supplement ) 369_2 - 369_2   2020年

<p>【目的】mTOR阻害薬エベロリムス (EVR) の副作用に脂質異常症があるが、機序解明に繋がる臨床データは少ない。今回LDLコレステロールとその上昇に関与するPCSK9濃度に及ぼすEVRの影響と、mTORC1及びPCSK9遺伝子多型の影響について検討した。【方法】腎移植患者53名を対象に、患者背景、EVR血中濃度、PCSK9濃度を調査した。さらにmTORC1及びPCSK9遺伝子多型との関連を解析した。【結果】EVR投与後のPCSK9濃度は投与前に比べ有意に高く(214 vs 295ng/mL、P=0.004)、EVR AUC0-12とPCSK9濃度変化率との間に有意な相関が認められた (r=0.316、P=0.021)。加えてEVR投与後のPCSK9濃度変化率がmTORC1 rs2295080Gアレル保有患者で有意に高かった(P=0.006)。一方、PCSK9遺伝子多型およびLDLコレステロール濃度変化率は、PCSK9濃度変化率と相関しなかった。多変量解析よりmTORC1 rs2295080Gアレル保有患者、EVR AUC0-12、及び女性においてEVR投与後のPCSK9変化率の上昇に独立性が認められた。【考察】EVR誘発脂質異常症はPCSK9を介した機序が示唆された。さらにLDLコレステロール上昇は、PCSK9上昇と同時に起こるのではなく、その後徐々に上昇すると考える。</p>

DOI CiNii Research

Drug interactions between warfarin and lenvatinib in a patient with the CYP2C9*1/*3 and VKORC1-1639G/A genotype

Yagishita H.

Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics )  44 ( 6 ) 977 - 980   2019年12月

DOI

Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer

Ozeki T.

Scientific Reports ( Scientific Reports )  9 ( 1 )   2019年12月

DOI

Association of immunosuppressive agents and cytomegalovirus infection with de novo donor-specific antibody development within 1 year after renal transplantation

Fujiyama N.

International Immunopharmacology ( International Immunopharmacology )  76   2019年11月

DOI

TDMを活用したクリニカル・クエスチョンの解決 ～臨床薬剤師によるTDM研究・臨床応用の発展を期待して～

尾田 一貴, 三浦 昌朋, 榎屋 友幸

日本医療薬学会年会講演要旨集 ( 一般社団法人 日本医療薬学会 )  29 ( 0 ) S39 - S39   2019年11月

DOI CiNii Research

セントラル担当と病棟担当薬剤師とのクロストーク～効率化と連携を再考する～

赤嶺 由美子, 三浦 昌朋, 大本 暢子

日本医療薬学会年会講演要旨集 ( 一般社団法人 日本医療薬学会 )  29 ( 0 ) S10 - S10   2019年11月

DOI CiNii Research

疾患を超えて薬学的観点から多剤併用療法の理論を考える

竹内 裕紀, 井上 岳, 三浦 昌朋

日本医療薬学会年会講演要旨集 ( 一般社団法人 日本医療薬学会 )  29 ( 0 ) S45 - S45   2019年11月

DOI CiNii Research

Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma

Kobayashi T.

Medical Oncology ( Medical Oncology )  36 ( 6 )   2019年06月

DOI

Dasatinib and low-intensity chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia in a child with Down syndrome

Hirabayashi S.

Pediatric Blood and Cancer ( Pediatric Blood and Cancer )  66 ( 5 )   2019年05月

DOI

Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer

Nagahama M.

Medical oncology (Northwood, London, England) ( Medical oncology (Northwood, London, England) )  36 ( 5 )   2019年03月

DOI

Dasatinib and low‐intensity chemotherapy for Philadelphia chromosome‐positive acute lymphoblastic leukemia in a child with Down syndrome

Shinsuke Hirabayashi, Daisuke Hasegawa, Kaoru Yamamoto, Akira Nishimura, Yosuke Hosoya, Takuya Shuo, Nobutaka Kiyokawa, Masatomo Miura, Naoto Takahashi, Atsushi Manabe

Pediatric Blood & Cancer ( Wiley )  66 ( 5 ) e27612   2019年01月

DOI CiNii Research

Personalized medicine for oral molecular-targeted anticancer drugs

Miura M.

Folia Pharmacologica Japonica ( Folia Pharmacologica Japonica )  153 ( 2 ) 73 - 78   2019年

<p>分子標的抗がん剤の血中濃度は効果と相関するとされており，血中濃度の値を指標に初回の標準投与量を個々の患者に適した投与量へと調節する治療薬物濃度モニタリング（TDM）が臨床において導入されている．日本では現在イマチニブと腎細胞がん治療薬スニチニブに対して，TDM実施によって診療報酬が得られている．TDMを実施することで，これまでに寛解率の向上，寛解達成に至るまでの時間の短縮，生存期間の延長，逸脱率の低下，医薬品費の抑制など多くのメリットが確認されている．しかしTDMの実施には，最小有効濃度（MEC）と最小中毒濃度（MTC）のいずれかあるいは両者を明確にしておく必要がある．MTC以上では，抗がん剤による重篤な副作用を発現するリスクが高く，MEC以下では十分な抗腫瘍効果を期待できない．それゆえMECとMTCの間に抗がん剤の血中濃度を収めるように，投与量を調節しながら治療を進める．今，個々の分子標的抗がん剤において，これらMECとMTCというマーカーを見出す臨床研究が求められている．抗がん剤による治療開始前に行われる精密化に加え，治療開始後の精密化（個別化）を図り，個々の患者に適切な抗がん剤，そして適切な投与量でプレシジョン・メディシンを，一貫して実施していくことが望まれる．そのためには一方で，血中濃度を測定する高速液体クロマトグラフィー（HPLC）等の分析機器の正確性も求められる．本総説では，がん領域におけるTDMの意義について述べる．</p>

DOI PubMed CiNii Research

慢性骨髄性白血病治療薬チロシンキナーゼ阻害剤の血中濃度を用いた治療マネジメントupdate

三浦 昌朋, 高橋 直人

臨床血液 ( 一般社団法人 日本血液学会 )  60 ( 9 ) 1140 - 1147   2019年

<p>慢性骨髄性白血病治療薬として現在5つのチロシンキナーゼ阻害剤が使用可能である。各々の薬剤において，特定の血中濃度を指標に投与量を調節する治療法の有用性が確認されている。イマチニブは特定薬剤治療管理料が算定でき，ターゲット血中トラフ濃度（C0）を1,000 ng/m<i>l</i>にすることで，1年でのMMR達成率が37％から63％に上昇している。ニロチニブは490 ng/m<i>l</i>以上にすることでMMR達成が6ヶ月早まっており，C0値900 ng/m<i>l</i>でより深い寛解が得られる。ダサチニブはC0値を4.33 ng/m<i>l</i>以下の可能な限り検出させないことで胸水発現を抑えることができ，ボスチニブはC0値62 ng/m<i>l</i>を推移させることで，治療開始1年におけるMMR達成が有意に高まる。ポナチニブは21.3 ng/m<i>l</i>をターゲットに投与量を調節することで，血管閉塞性有害事象を回避した継続的治療の可能性が考えられている。本稿では血中濃度を用いた治療戦略の導入による治療成績の変化について概説する。</p>

DOI PubMed CiNii Research

Dietary intake of pyrolyzed deketene curcumin inhibits gastric carcinogenesis

Yoshida T.

Journal of Functional Foods ( Journal of Functional Foods )  50   192 - 200   2018年11月

DOI

Comparison of electrochemiluminescence immunoassay and latex agglutination turbidimetric immunoassay for evaluation of everolimus blood concentrations in renal transplant patients

Akamine Y.

Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics )  43 ( 5 ) 675 - 681   2018年10月

DOI

Curcumin analog, GO-Y078, overcomes resistance to tumor angiogenesis inhibitors

Shimazu K.

Cancer Science ( Cancer Science )  109 ( 10 ) 3285 - 3293   2018年10月

DOI

Risk of new-onset diabetes mellitus during treatment with low-dose statins in Japan: A retrospective cohort study

Kato S.

Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics )  43 ( 4 ) 536 - 542   2018年08月

DOI

Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan

Noguchi S.

International Journal of Hematology ( International Journal of Hematology )  108 ( 2 ) 176 - 183   2018年08月

DOI

Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia

Abumiya M.

Medical Oncology ( Medical Oncology )  35 ( 6 )   2018年06月

DOI

Phase II clinical trial of lenalidomide and dexamethasone therapy in Japanese elderly patients with newly diagnosed multiple myeloma to determine optimal plasma concentration of lenalidomide

Kobayashi T.

Therapeutic Drug Monitoring ( Therapeutic Drug Monitoring )  40 ( 3 ) 301 - 309   2018年06月

DOI

The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma

Kobayashi T.

Annals of Hematology ( Annals of Hematology )  97 ( 6 ) 1097 - 1099   2018年06月

DOI

Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients

Numakura K.

Oncotarget ( Oncotarget )  9 ( 38 ) 25277 - 25284   2018年05月

DOI

Influence of CYP3A5 genetic differences in tacrolimus on quantitative interstitial fibrosis and long-term graft function in kidney transplant recipients

Komine N.

International Immunopharmacology ( International Immunopharmacology )  58   57 - 63   2018年05月

DOI

特集 急性白血病の薬物療法のupdate ～最新の診断・治療戦略～ ８.治療薬物モニタリング

三浦昌朋, 高橋直人

医薬ジャーナル ( 医薬ジャーナル社 )  54 ( 5 ) 1244 - 1248   2018年05月

DOI CiNii Research

A comparison of the effects of CYP3A5 polymorphism on tacrolimus blood concentrations measured by 4 immunoassay methods in renal transplant patients

Akamine Y.

Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics )  43 ( 2 ) 181 - 188   2018年04月

DOI

An update on the clinical pharmacokinetics of fexofenadine enantiomers

Akamine Y.

Expert Opinion on Drug Metabolism and Toxicology ( Expert Opinion on Drug Metabolism and Toxicology )  14 ( 4 ) 429 - 434   2018年04月

DOI

Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma

Igarashi R.

Medical Oncology ( Medical Oncology )  35 ( 4 )   2018年04月

DOI

Correlation of plasma concentration and adverse effects of bosutinib: Standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia

Mita A.

Experimental Hematology and Oncology ( Experimental Hematology and Oncology )  7 ( 1 )   2018年04月

DOI

Prediction of tacrolimus exposure by CYP3A5 genotype and exposure of co-administered everolimus in Japanese renal transplant recipients

Kagaya H.

International Journal of Molecular Sciences ( International Journal of Molecular Sciences )  19 ( 3 )   2018年03月

DOI

第Ⅲ部　治療における最近の新薬の位置付け〈薬効別〉～新薬の広場～ 免疫抑制剤

赤嶺由美子, 三浦昌朋

医薬ジャーナル ( 医薬ジャーナル社 )  54 ( 13 ) 519 - 525   2018年02月

DOI CiNii Research

Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients

Abumiya M.

Leukemia Research ( Leukemia Research )  64   42 - 45   2018年01月

DOI

がん治療時に遭遇する薬物相互作用とその対策を考える

三浦 昌朋, 富岡 佳久

日本医療薬学会年会講演要旨集 ( 一般社団法人 日本医療薬学会 )  28 ( 0 ) 352 - 357   2018年

DOI CiNii Research

Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non–small-cell Lung Cancer

Yokota H.

Clinical Lung Cancer ( Clinical Lung Cancer )  18 ( 6 ) e433 - e439   2017年11月

DOI

Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms

Akamine Y.

Annals of Clinical Biochemistry ( Annals of Clinical Biochemistry )  54 ( 6 ) 677 - 685   2017年11月

DOI

Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations

Niioka T.

Clinical and Experimental Nephrology ( Clinical and Experimental Nephrology )  21 ( 5 ) 787 - 796   2017年10月

DOI

Relationship between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N -Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients with Different CYP2C19 Genotypes

Niioka T.

Therapeutic Drug Monitoring ( Therapeutic Drug Monitoring )  39 ( 5 ) 514 - 521   2017年10月

DOI

Therapeutic strategy of tyrosine kinase inhibitors using plasma concentration

Miura M.

Japanese Journal of Clinical Chemistry ( Japanese Journal of Clinical Chemistry )  46 ( 4 ) 277 - 282   2017年10月

Plasma concentration of osimertinib in a non-small cell lung cancer patient with chronic renal failure undergoing hemodialysis

Tamura T.

Lung Cancer ( Lung Cancer )  112   225 - 226   2017年10月

DOI

Quantification of interstitial fibrosis in renal allografts and clinical correlates of long-Term graft function

Nara M.

American Journal of Nephrology ( American Journal of Nephrology )  46 ( 3 ) 187 - 194   2017年09月

DOI

Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival

Okuda Y.

Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology )  79 ( 5 ) 1013 - 1020   2017年05月

DOI

Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib

Numakura K.

Anti-Cancer Drugs ( Anti-Cancer Drugs )  28 ( 1 ) 97 - 103   2017年01月

DOI

Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation

Kagaya H.

Xenobiotica ( Xenobiotica )  47 ( 10 ) 916 - 922   2017年

DOI

免疫抑制薬TDM標準化ガイドラインversion2の策定と今後

増田 智先, 三浦 昌朋

日本医療薬学会年会講演要旨集 ( 一般社団法人 日本医療薬学会 )  27 ( 0 ) 236 - 244   2017年

DOI CiNii Research

薬剤師による麻酔薬調製と麻薬管理が及ぼす手術患者入れ替え時間への影響

加藤 正太郎, 合谷木 徹, 岩澤 さあや, 堀口 剛, 西川 俊昭, 三浦 昌朋

日本臨床麻酔学会誌 ( 日本臨床麻酔学会 )  37 ( 3 ) 295 - 300   2017年

<p>手術患者入れ替え時間の短縮は手術件数増加の重要な要因となる．秋田大学医学部附属病院では2009年より薬剤師1名が手術室に専従し，麻酔薬調製および麻薬管理を行ってきた．今回われわれは，過去に行った7診療科の患者入れ替え時間を調査し薬剤師専従開始前後で比較した．その結果，専従開始後の患者入れ替え時間は専従開始前と比較して中央値13.0分間有意に短縮し，診療科別の検討でもすべてにおいて時間が短縮した．薬剤師が麻酔科医に代わって麻酔薬調製および麻薬管理をすることで患者入れ替え時間の短縮に繋がり，手術件数の向上に貢献できると考えられる．</p>

DOI CiNii Research

分子標的抗がん剤の個別化医療　血中濃度測定と臨床応用

三浦 昌朋

日本病院薬剤師会雑誌   53   1479 - 1483   2017年

CiNii Research